LETHA SUNIL: Open Payments
NPI 1053952531 · OLNEY, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,399 in 64 payments from 8 companies in 2025. Trend: 2023 $179 · 2024 $583 · 2025 $1,399
Food & beverage: $1,391Education: $8
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 26 | $574 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $221 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $180 |
| Lundbeck LLC | 6 | $150 |
| Otsuka America Pharmaceutical, Inc. | 7 | $145 |
| Neurocrine BioSciences, Inc. | 3 | $65 |
| Supernus Pharmaceuticals, Inc. | 3 | $48 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
Products named: VRAYLAR, REXULTI, CAPLYTA, TRINTELLIX, INGREZZA, Qelbree, AUSTEDO XR.
Industry payments across MD — which companies pay providers there.
